COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03286101
Recruitment Status : Completed
First Posted : September 18, 2017
Last Update Posted : March 7, 2018
Information provided by (Responsible Party):
United Laboratories

Brief Summary:
This is a randomized, double-blind, placebo-controlled clinical study evaluating the efficacy and safety of a single application of 0.5% ivermectin lotion in Filipino subjects with head lice.

Condition or disease Intervention/treatment Phase
Pediculosis Capitis Drug: 0.5% Ivermectin lotion Drug: Vehicle Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial On The Efficacy And Safety Of Topical 0.5% Ivermectin Lotion For The Treatment Of Head Lice Infestation Among Filipino Children Age 3 Years Or Older
Actual Study Start Date : September 14, 2017
Actual Primary Completion Date : October 12, 2017
Actual Study Completion Date : November 9, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Ivermectin

Arm Intervention/treatment
Experimental: 0.5% Ivermectin Lotion Drug: 0.5% Ivermectin lotion
The intervention is composed of a single application of the 0.5% ivermectin lotion.

Placebo Comparator: Vehicle control Drug: Vehicle
The intervention is composed of a single application of the vehicle control.

Primary Outcome Measures :
  1. Proportion of participants cured of head lice infestation from their assigned product on day 2, day 8 and day 15 after the first treatment. [ Time Frame: Day 2 to day 15 after product application ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Index subjects must have an active lice infestation defined as: At least 3 live lice (adult and/or nymphs) present on the scalp and/or hair as determined by a trained evaluator; After the index subject has been enrolled, additional infested household members will be enrolled.
  • Household subjects must have an active head lice infestation defined as: At least 1 live louse (adult and /or nymph) present on the scalp and/or hair, as determined by a trained evaluator (with the exception of the male head of household who may self- assess, as being lice free).
  • Subject is male or female;
  • Subject is at least 3 years old or older at the time of enrollment;
  • Subject is in good general health based on the medical history;
  • Each adult subject must have an appropriately signed Informed Consent agreement. For children, parents/guardian must sign an Informed Parental Consent agreement for children not old enough to do so. Children of a specified age will be administered a child's assent form
  • The caregiver of a subject must be willing to allow all household members to be screened for head lice. If other household members are found to have an active head lice infestation, they must be willing and able to participate in the study. No more than one working male per household maybe excluded from evaluation if he is assessed as being lice free by himself or the caregiver and cannot come in due to his work schedule. If this individual may have lice, he must come to the test facility, otherwise the entire household will be excluded from study participation.
  • Subject and/or caregiver must be physically able and willing to report to the testing center for the supervised application of the product.
  • Subjects agrees not to use any other form of lice treatment (commercial or mechanical/manual) while participating in the study;
  • Following application and rinsing of the test product, subject agrees not to shampoo / wash, or rinse their hair or scalp until the 24-hour post treatment evaluation has been completed;
  • Subject agrees to not cut or chemically treat their hair while participating in the study;
  • Subject agrees to follow all study instructions.

Exclusion Criteria:

  • History of irritation or sensitivity to ivermectin or lotion components pediculosis or hair care products;
  • Presence of visible skin / scalp conditions that are not attributable to head lice infestation, such as erythema, blisters, vesicles which in the opinion of the investigative personnel will interfere with safety and / or efficacy evaluations;
  • Subjects suffering from psoriasis, atopic dermatitis or other conditions, which in the opinion of the investigator may compromise the objective of the study;
  • Treatment for head lice (OTC, home remedy or Rx) in the last 14 days;
  • Subjects under treatment which in the opinion of the investigator will interfere with the study results;
  • Subjects who participated in a previous investigational drug study within the past 30 days;
  • Subjects who does not understand the requirements for the study participation and/ or likely exhibit poor compliance, in the opinion of the investigator;
  • Females who are pregnant or lactating.
  • Living in a household where at least one member is pregnant, lactating, or planning a pregnancy
  • Subjects with skin lesions, specifically skin breaks are excluded because of possible absorption of the drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03286101

Layout table for location information
Clinical Trial Management and Testing Associates, Inc.
Muntinlupa, Philippines
Sponsors and Collaborators
United Laboratories
Layout table for investigator information
Principal Investigator: Gertrude Chan, M.D. Clinical Trial Management and Testing Associates, Inc.
Layout table for additonal information
Responsible Party: United Laboratories Identifier: NCT03286101    
Other Study ID Numbers: RD2017-01
First Posted: September 18, 2017    Key Record Dates
Last Update Posted: March 7, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lice Infestations
Parasitic Diseases
Ectoparasitic Infestations
Skin Diseases, Parasitic
Skin Diseases, Infectious
Skin Diseases
Antiparasitic Agents
Anti-Infective Agents